Loading news...
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) is set to deliver a solid finish to 2025 when it reports fourth-quarter results next month, according to JP Morgan,...
AstraZeneca PLC (LON: AZN - Get Free Report) insider Nazneen Rahman sold 297 shares of the company's stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of £134.96, for a total value of £40,083.12. AstraZeneca Trading Down 0.5% Shares of AstraZeneca stock opened at £136.02 on Tuesday. The company's
Shares of AstraZeneca PLC (LON: AZN - Get Free Report) hit a new 52-week high during mid-day trading on Friday. The stock traded as high as £154.74 and last traded at £135.85, with a volume of 422522813 shares trading hands. The stock had previously closed at £135.48. Analyst Upgrades and Downgrades Several brokerages recently commented
AstraZeneca PLC (LON: AZN - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of £117.76 and traded as high as £136.88. AstraZeneca shares last traded at £135.96, with a volume of 558,747,313 shares. Analyst Upgrades and Downgrades Several brokerages recently issued reports
Early data indicate that BI-1206 has the potential to reset one of the main resistance mechanisms to rituximab 47% of patients exhibited complete responses (CR), with an overall response rate of 80% Favorable safety profile with most (87%) adverse events being mild or moderate and no treatment-related discontinuations The safety run-in portion is complete with no apparent differences in safety or efficacy between the two dose levels; the signal-seeking expansion phase of the study is ongoing LUND, SE / ACCESS Newswire / December 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune‑modulatory antibodies for cancer immunotherapy, today announced the presentation of new data from the safety run-in portion of its ongoing trial evaluating BI-1206, an anti-FcγRIIB antibody, in combination with rituximab and Calquence® (acalabrutinib) for the treatment of non-Hodgkin's lymphoma (NHL) at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. Anti-CD20 antibodies like rituximab are essential for treating NHL.
9.16am: European markets in selling mode After the first hour and a bit of trading, the Footsie is down 0.8%, which is one of the better performances among...
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) investors might want to take a deep breath. Deutsche Bank has turned bearish on the UK drugmaker, cutting its rating...
Shares in IXICO PLC (LSE:IXI, OTC:PHYOF) climbed 4% to 13p after the neuroscience data firm reported a 13% rise in annual revenue to £6.5 million, exceeding...
Anglo Asian Mining Plc (LSE:AAZ, OTC:AGXKF) told investors it has seen record quarterly copper production of 2,287 tonnes for the three months to 30...
Iofina PLC (AIM:IOF, OTC:IOFNF) told investors it has achieved record quarterly production of 215.8 metric tonnes of crystalline iodine in Q3 2025, a 32%...
Coinsilium Group Limited (AQSE:COIN, OTCQB:CINGF) has restructured its board and signalled a strategic shift as it prepares for a busier phase of activity...